BioAcyl Corp
BioAcyl Corp |
|
 |
 |
 |
|
Woodruff, M., Ramonell, R., Cashman, K., Nguyen, D., Saini, A., & Haddad, N., et al. (2020). Dominant extrafollicular B cell responses in severe COVID-19 disease correlate with robust viral-specific antibody production but poor clinical outcomes. medRxiv, 2020.04.29.20083717. Added by: Dr. Enrique Feoli (03/10/2020, 14:02) Last edited by: Dr. Enrique Feoli (03/10/2020, 14:03) |
 |
| Resource type: Journal Article BibTeX citation key: Woodruff2020 View all bibliographic details  |
Categories: Subcategories: Creators: Anam, Cashman, Chen, Derrico, Estrada, Haddad, Howell, Hu, Jenks, Kyu, Le, Lee, Lee, Ley, Morrison-Porter, Nguyen, Ozturk, Ramonell, Saini, Sanz, Sharma, Tipton, Woodruff, Wu Collection: medRxiv |
Views: 3/268
|
| Abstract |
|
{A wide clinical spectrum has become a hallmark of the SARS-CoV-2 (COVID-19) pandemic, although its immunologic underpinnings remain to be defined. We have performed deep characterization of B cell responses through high-dimensional flow cytometry to reveal substantial heterogeneity in both effector and immature populations. More notably, critically ill patients displayed hallmarks of extrafollicular B cell activation as previously described in autoimmune settings. Extrafollicular activation correlated strongly with large antibody secreting cell expansion and early production of high levels of SARS-CoV-2-specific antibodies. Yet, these patients fared poorly with elevated inflammatory biomarkers, multi-organ failure, and death. Combined, the findings strongly indicate a major pathogenic role for immune activation in subsets of COVID-19 patients. Our study suggests that, as in autoimmunity, targeted immunomodulatory therapy may be beneficial in specific patient subpopulations that can be identified by careful immune profiling.}
|